Nomura Adjusts Jiangsu Hengrui Medicine's Price Target to 48.32 Yuan From 51.12 Yuan, Keeps at Neutral
Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Liver Disease Treatment
Jiangsu Hengrui Pharmaceuticals (600276.SH): Hydroxyethylsulfonate Dalsilepin tablets and HRS-1358 tablets have obtained drug clinical trial approval.
On July 21st, Gelunhui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) and its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. recently received the Approval Notice for Clinical Trials of Hydroxyethanesulfonic Acid Daxcelipine Tablets and HRS-1358 Tablets issued by the National Medical Products Administration, and will conduct clinical trials in the near future. Hydroxyethanesulfonic Acid Daxcelipine Tablets (trade name: Airicon) has been approved for two indications, respectively: in December 2021, it was approved for use in combination with Fluvestrant for Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer patients who have undergone endocrine therapy.
Zhao Bei's second-quarter report for ICBC Credit Suisse Fund has been released! Jiangsu Hengrui Pharmaceuticals (600276.SH) is the top holding.
On July 18th, the fund under Zhao Bei's management at ICBC Credit Suisse Fund released its Q2 report for 2024.
Ping An Securities: Nuclear medicine has multiple clinical advantages, and high barriers to entry have created an oligopolistic monopoly pattern.
It is expected that from 2023 to 2030, China's nuclear medicine market will grow from 5 billion yuan to 26 billion yuan at a CAGR of 26.6%.
Market Chatter: Jiangsu Hengrui Medicine Vows to Improve Production Following FDA Warning
Jiangsu Hengrui Pharmaceuticals (600276.SH): Currently, the company's export products to the USA are unaffected.
Jiangsu Hengrui Pharmaceuticals (600276.SH) stated on the interactive platform on July 17th that the FDA warning letter the company received this time is related to the previous Form 483, both of which are related to the inspection of a formulation production site in the Lianyungang area by the FDA. At present, the export of products to the United States is not affected, and there is no impact on the company's other production sites, which will not have a significant impact on the company's performance. In response to the improvement suggestions raised by the FDA in this warning letter, the company will actively organize internal and external experts and third-party consulting institutions to implement relevant suggestions, maintain close communication with the FDA, and strive to close the warning letter as soon as possible.
Hengrui received an FDA warning letter | Jianzhi Research
A problem that should not have been present arose from a leader. Following the June FORM483 incident, Hengrui has one more opportunity to rectify the issue.
Hengrui Medicine Gets Inspection Clearance From Jiangsu Province's Drug Regulator
Jiangsu Hengrui Pharmaceuticals' (600276.SH) subsidiary passed the pharmaceutical GMP compliance inspection.
On July 7th, Gelunhui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biomedical Pharmacy Co., Ltd., recently received a "Drug GMP Compliance Inspection Results Notice" issued by the Jiangsu Provincial Drug Administration. Inspection conclusion: Based on the results of this inspection and the review of the Jiangsu Provincial Drug Administration, Suzhou Shengdiya Biomedical Pharmacy Co., Ltd. complies with the "Drug Production Quality Management Standard (2010 Revision)" and its appendix. This GMP compliance inspection indicates that the production of related pharmaceuticals of the company meets GMP requirements, and will help the company maintain stable production.
Jiangsu Hengrui Pharmaceuticals (600276.SH) will distribute a cash dividend of 0.2 yuan per share for the year 2023 on July 12.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the profit distribution plan for this time has been approved on May 15, 2024...
Jiangsu Hengrui Medicine Gets Clinical Trial Approval for Pulmonary Fibrosis Drug
Jiangsu Hengrui Pharmaceuticals (600276.SH): Clinical trial application for HRS-9813 tablets approved.
Jiangsu Hengrui Pharmaceuticals (600276.SH) issued an announcement that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received the approval notice of drug clinical trial for HRS-9813 from the National Medical Products Administration and will conduct clinical trials in the near future. HRS-9813 is a Category 1 innovative drug independently developed by the company. Preclinical mouse IPF efficacy data showed that HRS-9813 can significantly improve lung function and pulmonary fibrosis with good safety.
The Price Is Right For Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)
CStone Pharmaceuticals Grants Exclusive Promotion Rights for Tumor Drug in China to Jiangsu Hengrui Medicine
Chi-Med-B (02616.HK) signed an exclusive promotion agreement with Jiangsu Hengrui Pharmaceuticals for Tjeenga (Afatinib tablets) in mainland China.
On July 3, Gelunhui announced that it has reached an agreement with Jiangsu Hengrui Pharmaceuticals to grant the exclusive promotion rights of precision therapy drug Tegiwa (Afatibine Tablets) in mainland China. In addition to the exclusive promotion rights granted to Hengrui Pharmaceutical, cornerstone Pharmaceuticals will continue to have the rights to research and development, registration, production, and distribution of Tegiwa in mainland China. With the cornerstone Pharmaceuticals' excellent clinical development capabilities, Tegiwa has become China's first drug for PDGFRA exon 18 mutation type (including D842V mutation) gastrointestinal stromal tumors (GIST).
Jiangsu Hengrui Medicine Gets US FDA Approval for Anesthetic; Shares Rise 4%
Express News | Jiangsu Hengrui Pharmaceuticals Says It Gets U.S. FDA's Approval for Bupivacaine Liposome Injection
Jiangsu Hengrui Pharmaceuticals (600276.SH) has obtained FDA approval number in the USA.
On July 2nd, Gelunhui reported that Jiangsu Hengrui Pharmaceuticals Co., Ltd. (stock code:600276.SH) announced that the company has received a notice from the U.S. Food and Drug Administration (FDA) that the company's Bupivacaine Liposome Injectable Suspension ANDA application has been approved, becoming the first manufacturer to obtain approval for this type of generic drug in the United States. Bupivacaine is a widely used amide local anesthetic for local anesthesia and postoperative analgesia in clinical settings. Compared with the 5-6 hour duration of action of ordinary injectables, the analgesic effect of bupivacaine liposome injection can be extended for several days due to its advanced technology.
Jiangsu Hengrui Pharmaceuticals (600276.SH) has repurchased 0.04% of its shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that as of June 30, 2024, the company has repurchased 2,514,504 shares through centralized bidding trading, accounting for 0.04% of the total share capital. The highest transaction price was 40.77 yuan/share, the lowest was 39.00 yuan/share, and the total amount paid was 100,151,305.00 yuan (excluding transaction fees).
No Data